- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07402915
Studio di interazione farmaco-farmaco con AZD5335 e Itraconazolo in partecipanti con carcinoma ovarico, peritoneale primario o delle tube di Falloppio
Uno studio in aperto, a sequenza fissa di Fase I per valutare l'effetto dell'itraconazolo (un forte inibitore del CYP3A) sulla farmacocinetica di AZ14170132, il payload inibitore TOP1 del coniugato anticorpo-farmaco AZD5335, in partecipanti con carcinoma ovarico, peritoneale primario o delle tube di Falloppio
The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This is a non-randomized, open-label, fixed sequence study to be conducted at multiple study centers.
The study will consist of 2 parts:
Part A of the study will comprise of:
- Screening period
- Treatment period: The treatment period will comprise of Cycles 1, 2 and 3 where the participants will receive AZD5335 along with itraconazole
- Follow-up visit (not applicable for participants involved in Part B)
Part B of the study will comprise of:
- Treatment period: Cycle 4 and onwards
- Safety Follow-up period
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Luoghi di studio
-
-
-
Batumi, Georgia, 6010
- Ritirato
- Research Site
-
Tbilisi, Georgia, 0114
- Ritirato
- Research Site
-
Tbilisi, Georgia, 112
- Ritirato
- Research Site
-
-
-
-
-
Dublin, Irlanda, D07 R2WY
- Reclutamento
- Research Site
-
-
-
-
-
Lisbon, Portogallo, 1250-068
- Reclutamento
- Research Site
-
-
-
-
-
Barcelona, Spagna, 08023
- Reclutamento
- Research Site
-
Logroño, Spagna, 26006
- Reclutamento
- Research Site
-
Madrid, Spagna, 28040
- Reclutamento
- Research Site
-
Madrid, Spagna, 28050
- Reclutamento
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participants with Platinum-resistant, relapsed, high- grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer and: (a) have received at least 1 prior line of platinum-containing chemotherapy and have progressed on or within 6 months after the date of the last dose of platinum; (b) must have received prior bevacizumab and/or Poly (ADP-ribose) polymerase (PARP) inhibitors according to local guidelines, unless ineligible.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Exclusion Criteria:
- Spinal cord compression or a history of leptomeningeal carcinomatosis.
- Unresolved toxicities of Grade ≥ 2 (National Cancer Institute-Common Terminology Criteria for Adverse Events v5.0) from prior therapy.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
- Uncontrolled intercurrent illness within 12 months prior to screening.
- Any other contraindication for receiving itraconazole according to the prescribing information and the Investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: AZD5335/AZD5335 + Itraconazole
In Part A, participants will receive AZD5335 alone as an intravenous (IV) infusion, and in combination with oral itraconazole, every 3 weeks (Q3W) from cycle 1 to cycle 3. In Part B, participants will receive AZD5335 as an IV infusion Q3W, from Day 1 of Cycle 4 until progression, unacceptable toxicity or any other specified criteria for discontinuation occurs. |
AZD5335 will be administered as IV infusion.
Altri nomi:
Itraconazole capsule will be administered orally. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the pharmacokinetics (PK) of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Maximum plasma drug concentration (Cmax)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
The effect of itraconazole on the PK of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Maximum plasma drug concentration (Cmax)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to time 17 days (AUC0-17days)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-17days of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Minimum plasma drug concentration (Cmin)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
Cmin of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Area under curve from time 0 to the time of last measurable concentration (AUC0-t)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
AUC0-t of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Terminal elimination (lambda_z)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
lambda_z of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Half life (t1/2)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
t1/2 of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Time to maximum observed concentration (tmax)
Lasso di tempo: Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
tmax of AZ14170132 will be assessed. |
Cycle 2 and Cycle 3 (each cycle is of 21 days)
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Lasso di tempo: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The safety and tolerability of AZD5335 alone and in combination with itraconazole will be assessed. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Objective response rate (ORR)
Lasso di tempo: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR), with the denominator defined as the number of participants in the response evaluable set. |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Duration of response (DoR)
Lasso di tempo: Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression). |
Part A: up to 121 days; Part B: up to 365 days post last participant first dose
|
|
Progression-free Survival (PFS)
Lasso di tempo: From Day 1 until until disease progression or death (up to 2 years)
|
The PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. |
From Day 1 until until disease progression or death (up to 2 years)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie genitali, femmina
- Neoplasie delle ghiandole endocrine
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Malattie delle tube di Falloppio
- Neoplasie ovariche
- Neoplasie delle tube di Falloppio
- Composti eterociclici, 1-anello
- Composti eterociclici
- Azoli
- Triazoli
- Piperazines
- Itraconazolo
Altri numeri di identificazione dello studio
- D8991C00002
- EU CT (Altro identificatore: 2025-522731-34-00)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitment a made to the EFPIA PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .